Gilead Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump Under Competitive Pressure

Hep C Tests Are A Good Idea For Baby Boomers
November 10, 2016
Metamucil (psyllium) for Constipation in Multiple Sclerosis
November 11, 2016
Show all

Gilead Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump Under Competitive Pressure

Gilead Sciences Inc.’s sales of Harvoni and Sovaldi, hepatitis C drugs, are lower than expected.

Gilead Sciences Inc. on Tuesday said sales of hepatitis C drugs Harvoni and Sovaldi missed expectations and slumped in the third-quarter, as the biopharmaceutical company faces challenges from rival drugs and pricing pressures.

For the latest quarter, Gilead reported Harvoni sales decreased 44% to $1.86 billion, while Sovaldi sales also fell 44% to $825 million. Analysts had expected Harvoni sales of $2.32 billion and Sovaldi sales of $1.06 billion, according to FactSet.

The declines were partly offset by sales of combination hepatitis C drug, Epclusa, which is priced lower than Harvoni and Sovaldi and generated sales of $640 million in the latest quarter, compared with sales of $64 million during the second quarter. Analysts expected Epclusa sales to reach $285.6 million, according to FactSet.

Read Full Article: Gilead Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump Under Competitive Pressure – WSJ

Read Full Article: Gilead Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump Under Competitive Pressure – WSJ

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.